Pacira’s Exparel Problems: CR Letter Stops New Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA finds issues with a supplemental application to use the pain treatment for nerve block shortly after Pacira gives 2015 financial guidance.
You may also be interested in...
Pacira's Exparel For Nerve Block Use Gets Day-Plus US FDA Panel Review
Pacira believes new clinical trial of post-surgical pain medication will satisfy FDA concerns raised in complete response letter for its supplemental NDA.
Keeping Track: Another Gene Therapy Approval, Several Priority Review Designations, And Many Resubmissions
The latest drug development news and highlights from our US FDA Performance Tracker.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.